PALI PALISADE BIO INC

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108

Carlsbad, CA, July 31, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a segment.

As part of this “What this Means” segment, Mitchell Jones, MD, PhD, Chief Medical Officer of Palisade Bio discusses the successful completion of a microbiome study confirming bacterial enzymes for local bioactivation of lead product candidate, PALI-2108, and what this means for its planned Phase 1 human clinical study for the treatment of Ulcerative Colitis.

The featuring Palisade Bio is now available here. Additional videos from the “What This Means” series are available on demand at .

About Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

833-475-8247



EN
31/07/2024

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635...

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended. The Company approved the issuance of an option to purchase 2,600 shares of the Company’s common stock to a new employee, a...

January 3, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisor...

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board. Dr. Feagan is a distinguished gastroenterologist with over 30 years of experience in the design, conduct, and execution of large-scale ran...

December 17, 2024 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Closing of $5 Million Underwritten Public Offer...

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comp...

December 13, 2024 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offer...

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 C...

December 12, 2024 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of...

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preliminary results fro...

December 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch